TWI610917B - 作爲ｇｐｒ１２０促效劑之硫基芳基衍生物 - Google Patents

作爲ｇｐｒ１２０促效劑之硫基芳基衍生物 Download PDF

Info

Publication number
TWI610917B
TWI610917B TW102140081A TW102140081A TWI610917B TW I610917 B TWI610917 B TW I610917B TW 102140081 A TW102140081 A TW 102140081A TW 102140081 A TW102140081 A TW 102140081A TW I610917 B TWI610917 B TW I610917B
Authority
TW
Taiwan
Prior art keywords
phenyl
ylmethoxy
pyridin
propionic acid
difluoro
Prior art date
Application number
TW102140081A
Other languages
English (en)
Chinese (zh)
Other versions
TW201431841A (zh
Inventor
金永寬
金明烈
朴相演
朴沃龜
瓦希利 阿特摩
李相大
朱顯雨
崔恩實
Original Assignee
南韓商Ｌｇ化學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商Ｌｇ化學股份有限公司 filed Critical 南韓商Ｌｇ化學股份有限公司
Publication of TW201431841A publication Critical patent/TW201431841A/zh
Application granted granted Critical
Publication of TWI610917B publication Critical patent/TWI610917B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
TW102140081A 2012-11-05 2013-11-05 作爲ｇｐｒ１２０促效劑之硫基芳基衍生物 TWI610917B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
??10-2012-0124502 2012-11-05
KR20120124502 2012-11-05

Publications (2)

Publication Number Publication Date
TW201431841A TW201431841A (zh) 2014-08-16
TWI610917B true TWI610917B (zh) 2018-01-11

Family

ID=50627764

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102140081A TWI610917B (zh) 2012-11-05 2013-11-05 作爲ｇｐｒ１２０促效劑之硫基芳基衍生物

Country Status (6)

Country Link
US (1) US9447044B2 (ja)
EP (1) EP2914580B1 (ja)
JP (1) JP6310931B2 (ja)
KR (1) KR101942752B1 (ja)
TW (1) TWI610917B (ja)
WO (1) WO2014069963A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974060C (en) 2015-02-05 2022-08-30 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
EP3429625B1 (en) 2016-03-15 2023-04-26 Queen Mary University of London Method of treatment of obesity
JP7065081B2 (ja) 2016-09-12 2022-05-11 インテグラル ヘルス， インコーポレイテッド Ｇｐｒ１２０モジュレーターとして有用な二環式化合物
CA3041033A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
RU2020132179A (ru) 2018-03-15 2022-04-15 Акссам С.П.А. Замещенные пиразолы, являющиеся агонистами рецептора FFA4/GPR120
US20210236443A1 (en) * 2018-04-20 2021-08-05 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
KR102404012B1 (ko) * 2019-06-24 2022-05-30 아주대학교 산학협력단 비알코올성 지방간 질환 예방 또는 치료용 약학 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206741A2 (en) * 1985-06-18 1986-12-30 Merck Frosst Canada Inc. Leukotriene antagonists
EP0536400A1 (en) * 1990-06-22 1993-04-14 Nippon Shinyaku Company, Limited Tetrazole derivative and medicine
WO2002042273A2 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002100403A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
WO2003027081A2 (en) * 2001-09-14 2003-04-03 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
WO2005051890A1 (en) * 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US20110082165A1 (en) * 2009-10-06 2011-04-07 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
AU2003254795A1 (en) * 2002-08-02 2004-02-23 Sankyo Company, Limited Resorcinol derivative
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7714008B2 (en) * 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
US8367708B2 (en) 2006-12-01 2013-02-05 Msd K.K. Phenyl-isoxazol-3-ol derivative
AU2008218950A1 (en) 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of G protein-coupled receptors
JPWO2008139879A1 (ja) 2007-04-26 2010-07-29 ファルマフロンティア株式会社 Ｇ蛋白質共役型レセプター抑制剤および医薬
WO2009048527A1 (en) * 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
ES2423793T3 (es) 2008-05-26 2013-09-24 Genfit Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias
JPWO2009147990A1 (ja) 2008-06-02 2011-10-27 Ｍｓｄ株式会社 新規イソオキサゾール誘導体
KR20110082145A (ko) * 2008-10-21 2011-07-18 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１２０ 수용체 작동약 및 이의 용도
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010104195A1 (en) 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
DK3013796T3 (da) * 2013-06-27 2020-03-16 Lg Chemical Ltd Biarylderivater som gpr120-agonister

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206741A2 (en) * 1985-06-18 1986-12-30 Merck Frosst Canada Inc. Leukotriene antagonists
EP0536400A1 (en) * 1990-06-22 1993-04-14 Nippon Shinyaku Company, Limited Tetrazole derivative and medicine
WO2002042273A2 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002100403A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
WO2003027081A2 (en) * 2001-09-14 2003-04-03 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
WO2005051890A1 (en) * 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US20110082165A1 (en) * 2009-10-06 2011-04-07 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN Database，RN:122317-75-3 *

Also Published As

Publication number Publication date
US9447044B2 (en) 2016-09-20
JP6310931B2 (ja) 2018-04-11
WO2014069963A1 (en) 2014-05-08
EP2914580A1 (en) 2015-09-09
US20150291527A1 (en) 2015-10-15
TW201431841A (zh) 2014-08-16
EP2914580A4 (en) 2016-06-01
JP2015535279A (ja) 2015-12-10
EP2914580B1 (en) 2019-02-20
KR101942752B1 (ko) 2019-01-28
KR20140059138A (ko) 2014-05-15

Similar Documents

Publication Publication Date Title
TWI610917B (zh) 作爲ｇｐｒ１２０促效劑之硫基芳基衍生物
CA2442319C (en) Carboxylic acid derivative and salt thereof
JP6095580B2 (ja) 芳香環化合物
CN104245663B (zh) 二环化合物
DE602004011985T2 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
JP2010524932A (ja) 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸ｇｐｒ４０調節物質
AU2015293541A1 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
JP5684126B2 (ja) グルカゴンアンタゴニスト
EP1471049A1 (en) Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
KR20100090249A (ko) 치환된 비페닐 ｇｒｐ４０ 조절제
CN102292321B (zh) 作为前列环素(pgi2)受体调节剂用于治疗该受体相关病症的吡唑基取代的碳酸衍生物
JP2020502111A (ja) 新規フェニルプロピオン酸誘導体及びその用途
JP2008503588A (ja) 化学化合物
RU2169141C2 (ru) Производные фенилалкилкарбоновой кислоты и фармацевтическая композиция на их основе
JP2014527953A (ja) 代謝性疾患治療用ｏ−フルオロ置換化合物
JP2022522334A (ja) 新規な甲状腺模倣物
CN107162921B (zh) 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
JP2008540520A (ja) Ｇｌｙｒのモジュレータ又はアゴニストである安息香酸誘導体
TWI712600B (zh) 作為免疫調節劑的聯苯化合物及其用途
TW200408621A (en) Compounds
CN115916740A (zh) 拟甲状腺素药
JP4644601B2 (ja) アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
EP1891026A2 (en) Cycloalkylidene compounds as selective estrogen receptor modulators
CN109661387A (zh) 用于治疗肺纤维化的组合物
TW202225153A (zh) 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途